CSL upbeat on bird flu vaccine
 

The manufacturer announced today that new data from its pandemic influenza vaccine clinical trial program proved it was safe and well-tolerated.



It also had determined the ideal dose of antigen needed to produce a strong immune response against the H5N1 bird flu virus, CSL (csl.ASX:Quote,News) spokeswoman Rachel David said.



"What we have now is sufficient information to definitively put in a master file to the TGA to say we can make this product," she said.



"With the current strain we're looking at, the Indonesian strain, we should be able to vaccinate the Australian population within six months."



CSL shares jumped higher, and were quoted at $70.55 at 2.11pm AEST, up 60 cents on the day after hitting a high of $70.89.



Two other pharmaceutical companies, GlaxoSmithKline and Sanofi-Aventis, are also developing pandemic flu vaccines but CSL will be the first to file for registration in Australia.



Kaynak: SağlıkHaber